Abstract
Synthetic polymers are well known through their widespread use in biomedical materials, for example hip prostheses, contact lenses, vascular grafts and most recently as scaffolds for tissue engineering. Polymers are also routinely used as pharmaceutical excipients. Both these applications are far removed from the concept of “disease targeting.” However, the last decade has seen the emergence of several novel classes of therapeutic that exploit the properties of natural or synthetic water soluble polymers to provide opportunities for improved chemotherapy. They include biologically active polymeric drugs, polymer-drug conjugates, block copolymer micelles, polymer-protein conjugates and polymer-based non-viral vectors are currently being designed for gene delivery.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Duncan R., Dimitrijevic S. and Evagorou E.G. The role of polymer conjugates in the diagnosis and treatment of cancer. S.T.P. Pharma Sciences 1996; 6:237.
Duncan, R. Polymer conjugates for tumor targeting and intracytoplasmic delivery. The EPR effect as a common gateway? Pharm. Sci. and Tech. Today 1999; 2(11): 441.
Brocchini, S. and Duncan, R. Pendent drugs, release from polymers. In Encyclopaedia of Controlled Drug Delivery, E. Mathiowitz, ed. John Wiley & Sons, New York, 1999.
Ringsdorf, H. Structure and properties of pharmacologically active polymers. J. Pharm Sci. Polymer Symp.51; 1975: 135.
Duncan, R. Drug-polymer conjugates: potential for improved chemotherapy. AntiCancer Drugs 1992; 3:175.
Duncan R., Kopeckova-Rejmanova P., Strohalm J., Hume I.C., Lloyd J.B., Kopecek J. Anticancer agents coupled to N-(2-hydroxypropyl) methacrylamide copolymers. 2. Evaluation of daunomycin conjugates in vivo against L1210 leukemia. Brit J Cancer 1988; 57:147.
Duncan, R., Seymour, L.W, O’Hare, K.B., Flanagan, P.A., Wedge, S., Ulbrich, K., Strohalm, J., Subr, V., Spreafico, F., Grandi, M., Ripamonti, M., Farao M. and Suarato, A. Preclinical evaluation of polymer-bound doxorubicin. J. Cont. Rel. 1992; 19: 331.
V.R. Caiolfa, V.R., Zamal, M., Fiorini, A., Frigerio, E., D’Argy, R., Ghigleri, A., Farao, M., Angelucci, F. and Suarato, A. Polymer-bound camptothecin: Initial biodistribution and antitumor activity studies. J. Cont. Rel. 2000;65:105.
Meerum Terwogt, J.M., ten Bokkel Huinink, W.W., Schellens, J.H.M., Schot, M., Mandjes, I.A.M., Zurlo, M.G., Rocchetti, M., Rosing, H., Koopman, F.J. and Beijnen, J. Phase I clinical and pharmacokinetic study of PNU166945, a novel water soluble polymer-conjugated pro-drug of paclitaxel. Anti-Cancer Drugs 2001;12:315.
Dimitrijevic, S. and Duncan R. Synthesis and characterization of N-(2hydroxypropyl)methacrylamide (HPMA) copolymer-ementine conjugates. J. Bioact. Compat. Polymers 1998;3:165.
Searle F., Gac-Breton S., Keane R., Dimitrijevic S., Brocchini S., Duncan R. N- (2hydroxypropyl)methacrylamide copolymer-6(3-aminopropyl)-ellipticineconjugates, synthesis, characterization and preliminary in vitro and in vivo studies, Bioconj. Chem. 2001; 2: 711.
Kasuya, Y., Lu, Z-R., Kopekovâ, P., Minko, T., Tabibi, S.E. and Kopecek, J. Synthesis and characterization of HPMA copolymer aminopropylgeldanamycin conjugates. J. Cont. Rel. 2001;74(1–3):203.
Gianasi, E., Wasil, M., Evagorou, E.G., Keddle, A., Wilson, G. and Duncan, R. HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity. Eur. J. Cancer 1999;3:994.
Duncan, R., Hume, I.C., Yardley, H.J., Flanagan, P.A., Ulbrich, K., Subr, V., Strohalm, J. Macromolecular pro-drugs for use in targeted cancer chemotherapy: Melphalan covalently coupled to N-(2-hydroxypropyl)methacrylamide copolymers. J Controlled Rel 1991; 16: 121.
Ringsdorf, H., Schmidt, B., Ulbrich, K. Bis (2-chloroethyl)amine bound to copolymers of N-(2-hydroxypropyl)methacrylamide and methacryloylated oligopeptides via biodegradable bonds. Makromol Chem 1987;188:257.
Krinick, N.L., Rihova, B., Ulbrich, K., Strohalm, J., Kopecek, J. Targetable photoactivatable drugs 2. Synthesis of N-(2-hydroxypropyl)methacrylamide copolymer anti-Thy 1. 2 antibody-chlorin e6 conjugates and a preliminary study of their photodynamic effect on mouse splenocytes in vitro. Makromol Chem 1990;191:839.
Musila, R. and Duncan, R. Synthesis and evaluation of HPMA copolymer-melittin as a potential anticancer agent. J. Pharm. Pharmacol. 2000; 52: 51.
Przybylski, M., Fell, E., Ringsdorf, H., Zaharko, D. Pharmacologically active polymers. 17. Synthesis and characterization of polymeric derivatives of the antitumour agent methotrexate. Makromol Chem 1978;179.1719.
Soyez, H., Schacht, E., Vanderkerken, S: The crucial role of spacer groups in macromolecular pro-drug design. Adv. Drug Delivery Rev.,1996;21:81.
Matsumura, Y. and Maeda, H. A new concept for macromolecular therapies in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumour agent SMANCS. Cancer Res. 1986;6:6387.
Seymour, L.W., Miyamoto, Y., Brereton, M., Styger, P.S., Maeda, H., Ulbrich, K. and Duncan. R. Influence of molecular size on passive tumor-accumulation of soluble macromolecular drug carriers. Eur. J. Cancer, 1995; 5: 766.
Sat, Y.N., Burger, A.M., Fiebig, H.H., Sausville, E.A. and Duncan, R. Comparison of vascular permeability and enzymatic activation of the polymeric pro-drug HPMA copolymer-doxorubicin (PK1) in human tumor xenografts. American Association for Cancer Research 9O h Annual Meeting, Philadelphia, USA 1999.
Seymour, L.W., Ulbrich, K., Styger, P.S., Brereton, M., Subr, V., Strohalm, J. and Duncan, R. Tumoritropism and anticancer efficacy of polymer-based doxorubicin pro-drugs in the treatment of subcutaneous murine B16F10 melanoma. Br. J. Cancer 1994;70.•636.
Ke S., Milas L., Charnsangavej C., Wallace S. and Li C. Potentiation of radioresponse by polymer-drug conjugates. J. Cont. Rel. 2001;74(1–3):237.
Duncan, R., Seymour, L.C.W., Scarlett, L., Lloyd, J.B., Rejmanova, P. and Kopecek, J. Fate of N-(2-Hydroxypropyl)methacrylamide copolymers with pendant galactosamine residues after intravenous administration to rats. Biochimica et Biophysica Acta 1986;880:62.
Seymour, L.W., Ferry, D.R., Anderson, D., Hesslewood, S., Julyan, P.J., Payner, R., Doran, J., Young, A.M., Burtles, S., Kerr, D.J, Hepatic drug targeting: Phase I evaluation of polymer bound doxorubicin. J. Clin. Oncol. 2002;20:1668.
O’Hare, K.B., Duncan, R., Strohalm, J., Ulbrich, K. and Kopeckova, P. Polymeric drug-carriers containing doxorubicin and melanocyte-stimulating hormone: In vitro and in vivo evaluation against murine melanoma../. Drug Targeting 1993;1:217.
Flanagan, P.A., Duncan, R., Subr, V, Ulbrich, K. Kopeckova, P. and Kopecek, J. Evaluation of protein N-(2-hydroxypropyl)methacrylamide copolymer conjugates as targetable drug-carriers. 2. Body distribution of conjugates containing transferrin, anti-transferrin receptor antibody or anti-Thy 1.2 antibody and effectiveness of transferrin-containing daunomycin conjugates against mouse L1210 leukemia in vivo. J. Cont. Rel. 1992;19.•25.
Sunassee, K.R. The evaluation of polymer-peptide and polymer-protein conjugates for targeted melanoma chemotherapy. PhD Thesis University of Keele, UK 1994.
Omelyanenko V., Kopeckova P. Prakash R.K., Ebert C.D. Kopecek J. Biorecognition of HPMA copolymer-adriamycin conjugates by lymphoctes mediated by synthetic receptor binding epitopes. Pharm. Res. 1999;16:1010.
Krinick, N.L., Rihova, B., Ulbrich, K., Strohalm, J. and Kopecek, J. Targetable photoactive drugs. 2. Synthesis of N-(2-hydroxypropyl)methacrylamide copolymeranti-Thy 1.2 antibody-chlorin e6 conjugates and a preliminary study of their photodynamic effect on mouse splenocytes in vitro. Makromol Chem 1990;191:839.
Rihova, B., Jelinkova, M., Strohalm, J., St’astny, M., Hovorka, O., Plocova, D., Kovar, M., Draberova, L. and Ulbrich, K. Antiproliferative effect of a lectin-and anti-Thy-1.2 antibody-targeted HPMA copolymer-bound doxorubicin on primary and metastatic human colorectal carcinoma and on human colorectal carcinoma transfected with the mouse Thy-1.2 gene. Bioconj. Chem. 2000;11(5):664.
St’astny, M., Strohalm, J., Plocova D., Ulbrich, K. and Rihova, B. A possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrier. Eur. J. Cancer 1999;35(3);459.
Rihova, B., Strohalm, J., Kubackova, K., Jelinkova, M., Hovorka, O., Kovar, M., Plocova, D., Sirova, M., St’astny, M., Rozprimova, L. and Ulbrich, K. Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugs. J. Cont. Rel. 2002; 78 (1–3): 97.
Omelyanenko, V., Gentry, C., Kopeckova, P. and Kopecek, J. HPMA copolymer anticancer drug OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro. Int. J. Cancer 1998;75(4):600.
Danauser-Reidl, S. Hausmann, E. Schick, H., Bender, R., Dietzfelbinger, H., Rastetter J. and Hanauske, A. Phase-I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Invest. New Drugs,1993;11:187.
Vasey, P., Twelves, C., Kaye, S., Wilson, P., Morrison, R., Duncan, R., Thomson, A., Hilditch, T., Murray, T., Burtles, S. and Cassidy, J. Phase I clinical and pharmacokinetic study of PKI (HPMA copolymer doxorubicin) first member of a new class of chemotherapeutics agents: drug-polymer conjugates. Clin. Cancer Res. 1999; 5: 83.
Twelves, C. Clinical experience with MAG-CPT. Proc. 5th Int Symp. Polymer Therap.: Laboratory to Clinic Cardiff, UK 2002.
Bolton, M.G., Kudekla, A., Cassidy, J., Calvert, H. Phase I studies of PGpaclitaxel(CT-2103) as a single agent and in combination with cisplatin. Proc. 5th Int Symp. Polymer Therap.: Laboratory to Clinic Cardiff UK 2002.
Sabbatini P., Aghajanian C., Hensley M., Pezzulli S., Oflaherty C., Soigner S. Lovegren M., Esch J., Funt S., Odujinrin O., Warner M., Bolton M.G. Spriggs D. Early findings in a Phase I/II study of PG-paclitaxel (CT-2103) in recurrent ovarian or primary peritoneal cancer. Proc. 5th Int Symp. Polymer Therap.: Laboratory to Clinic Cardiff, UK 2002.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media New York
About this chapter
Cite this chapter
Duncan, R. (2002). Polymer-Drug Conjugates: Targeting Cancer. In: Muzykantov, V., Torchilin, V. (eds) Biomedical Aspects of Drug Targeting. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-4627-3_10
Download citation
DOI: https://doi.org/10.1007/978-1-4757-4627-3_10
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-5312-4
Online ISBN: 978-1-4757-4627-3
eBook Packages: Springer Book Archive